Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	XL147	1	72	flat	flat	HCC70 pilaralisib 0 1 72	8	1.396	Inf	1.05	-0.0406	0.0	1.05	0.01	-0.285	1.0	1.03	Inf	1.04	1.03	0.0	1.04	0.01	-0.295	1.0	1.02
HCC70	XL147	3	72	flat	flat	HCC70 pilaralisib 0 3 72	8	2.478	Inf	1.03	-0.0199	0.0	1.03	0.01	-0.318	1.0	1.02	Inf	1.03	1.03	0.0	1.03	0.01	-0.331	1.0	1.02
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	0.0	1.02	0.01	-0.00881	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
HCC1806	AZD-6482	1	72	flat	flat	HCC1806 AZD6482 0 1 72	8	2.748	Inf	1.0	0.00141	0.0	1.0	0.01	-0.00621	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
BT-20	MK2206	2	72	sigmoid	sigmoid	BT20 MK-2206 0 2 72	8	1.739	0.823	0.0896	0.246	4.34	-1.0	0.661	0.965	4.36e-05	NA	1.47	0.348	0.806	1.47	0.0	0.715	0.947	0.000145	NA
BT-20	Torin2	3	72	sigmoid	sigmoid	BT20 Torin2 0 3 72	8	2.458	0.019	-0.64	0.751	0.234	-1.0	0.438	0.959	6.92e-05	NA	0.0147	0.0148	0.379	0.0123	0.0598	0.727	0.977	1.28e-05	NA
BT-20	PIK-93	2	72	sigmoid	sigmoid	BT20 PIK-93 0 2 72	8	1.798	0.792	0.155	0.286	14.1	-1.0	0.382	0.81	0.00687	NA	2.8	0.373	0.764	2.8	0.0	0.344	0.77	0.0121	NA
BT-20	AZD-6482	3	72	sigmoid	sigmoid	BT20 AZD6482 0 3 72	8	2.601	1.68	0.3	0.173	8.38	-1.0	0.685	0.959	6.72e-05	NA	1.5	0.326	0.805	1.5	0.0	0.733	0.925	0.000414	NA
BT-549	Pictilisib	2	72	sigmoid	sigmoid	BT549 pictilisib 0 2 72	8	1.960	1.84	0.365	0.166	11.5	-1.0	0.599	0.943	0.000187	NA	2.82	0.473	0.851	2.82	0.0	0.647	0.924	0.000432	NA
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
BT-549	PIK-93	3	72	sigmoid	sigmoid	BT549 PIK-93 0 3 72	8	1.807	20.1	0.719	0.0848	231.0	-1.0	0.45	0.716	0.0229	NA	67.9	0.761	0.925	67.9	0.0	0.431	0.686	0.0309	NA
BT-20	Pictilisib	2	72	sigmoid	sigmoid	BT20 pictilisib 0 2 72	8	1.746	0.308	-0.0521	0.379	2.35	-1.0	0.54	0.791	0.00908	NA	0.634	0.272	0.712	0.634	0.0	0.6	0.716	0.0229	NA

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)